Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3g vs 2g Mycophenolate Mofetil in Kidney Transplant Recipients
NCT01860183Phase 4
Key facts
- Status
- Completed
- Start
- May 2013
- Primary completion
- Jun 2016
- Countries
- 1
- Sponsor
- Clinical Hospital Merkur
- Modality
- Small Molecules
- Conditions
- kidney failure (ESRD)
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in kidney failure (ESRD), sponsored by Clinical Hospital Merkur. Primary endpoint: Progression of interstitial fibrosis (ci) at 1 year. Started May 2013; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
First kidney or kidney-pancreas transplant recipients with low immunological risk (PRA <= 20%) and minimal baseline chronic histological changes (biopsy score < 2).
04
Endpoints
Primary
Progression of interstitial fibrosis (ci)
Beyond the preview
Go deeper on NCT01860183.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860183.